Oxaloacetate supplement eased brain fog and fatigue after breast cancer treatment

A small UCLA phase II trial found that eight weeks of oxaloacetate supplementation improved cognition in 16 breast cancer survivors. The average perceived cognitive impairment score rose from 29.1 to 55.5, and fatigue dropped. A randomized placebo-controlled trial is expected in late 2026.

• 16 participants completed eight weeks of 500 mg oxaloacetate twice daily
• Cognitive impairment score rose from 29.1 to 55.5, moving into the normal range
• Improvements appeared by week four and grew by week eight
• A placebo-controlled phase II trial is expected in late 2026